Realm Therapeutics continues to assess options available to maximize shareholder value through the strategic review.
The Company remains in discussions regarding potential strategic transactions which may subsequently result in either a takeover offer for the Company or an acquisition constituting a reverse merger, or, if a suitable strategic transaction is not identified, a potential winding down of the Company and distribution to Shareholders of the Company's remaining assets following satisfaction of all applicable liabilities and obligations. At the current time discussions are ongoing with a number of interested parties, some of whom are interested in a reverse takeover transaction (which would involve an acquisition of a business or corporate entity in the life sciences sector, where the potential offeror would acquire the benefit of the Company's Nasdaq listing and cash) and others, who are potential offerors, are interested in making a takeover offer for the Company (in order to access the Company's cash).
public listing on the Nasdaq Capital Market
cash at December 31, 2018 of $18.8 million